AVALO THERAPEUTICS, INC. Earnings Per Share, Basic and Diluted
AVALO THERAPEUTICS, INC. (AVTX) reported Earnings Per Share, Basic and Diluted of -$1.20 per share for the 12-month period ending 2018-12-31, per its 10-K filed 2020-03-11.
Discontinued › Income Statement › Earnings Per Share
us-gaap:EarningsPerShareBasicAndDiluted · last filed 2020-03-11
- AVALO THERAPEUTICS, INC. earnings per share, basic and diluted for the quarter ending 2018-09-30 was -$0.71, a 236.54% decline year-over-year.
- AVALO THERAPEUTICS, INC. earnings per share, basic and diluted for the quarter ending 2018-06-30 was -$0.19.
- AVALO THERAPEUTICS, INC. earnings per share, basic and diluted for the quarter ending 2018-03-31 was -$0.12.
- AVALO THERAPEUTICS, INC. earnings per share, basic and diluted for the quarter ending 2017-09-30 was $0.52.
- AVALO THERAPEUTICS, INC. earnings per share, basic and diluted for fiscal 2018 was -$1.20.
- AVALO THERAPEUTICS, INC. earnings per share, basic and diluted for fiscal 2016 was -$1.87.
- AVALO THERAPEUTICS, INC. earnings per share, basic and diluted for fiscal 2015 was -$4.71.
- AVALO THERAPEUTICS, INC. earnings per share, basic and diluted for fiscal 2014 was -$5.48.
| Period end | Earnings Per Share, Basic and Diluted 3 month | Earnings Per Share, Basic and Diluted 3 month as first filed | Earnings Per Share, Basic and Diluted 6 month | Earnings Per Share, Basic and Diluted 9 month | Earnings Per Share, Basic and Diluted 12 month |
|---|---|---|---|---|---|
| 2018-12-31 | -$1.20 10-K · filed 2020-03-11 | ||||
| 2018-09-30 | -$0.71 10-Q · filed 2018-11-13 | -$1.05 10-Q · filed 2018-11-13 | |||
| 2018-06-30 | -$0.19 10-Q · filed 2018-08-09 | -$0.31 10-Q · filed 2018-08-09 | |||
| 2018-03-31 | -$0.12 10-Q · filed 2018-05-11 | ||||
| 2017-09-30 | $0.52 10-Q · filed 2018-11-13 | $0.65 10-Q · filed 2018-11-13 | |||
| 2017-06-30 | -$0.14 10-Q · filed 2018-08-09 | -$0.32 10-Q · filed 2018-08-09 | |||
| 2017-03-31 | -$0.19 10-Q · filed 2018-05-11 | ||||
| 2016-12-31 | -$0.18 10-K · filed 2018-04-02 | -$0.87 derived: net income ÷ weighted average shares · filed 2018-04-02 | -$1.87 10-K · filed 2017-03-14 | ||
| 2016-09-30 | -$0.70 10-K · filed 2018-04-02 | -$1.71 10-Q · filed 2017-11-07 | |||
| 2016-06-30 | -$0.41 10-K · filed 2018-04-02 | -$1.00 10-Q · filed 2017-08-14 | |||
| 2016-03-31 | -$0.59 10-K · filed 2018-04-02 | ||||
| 2015-12-31 | -$0.53 10-K · filed 2017-03-14 | -$1.14 derived: net income ÷ weighted average shares · filed 2017-03-14 | -$2.64 derived: net income ÷ weighted average shares · filed 2017-03-14 | -$4.71 10-K · filed 2017-03-14 | |
| 2015-09-30 | -$1.06 10-K · filed 2017-03-14 | -$5.55 derived: net income ÷ weighted average shares · filed 2016-11-08 | -$10.53 10-Q · filed 2016-11-08 | -$14.45 derived: net income ÷ weighted average shares · filed 2017-03-14 | |
| 2015-06-30 | -$4.48 10-K · filed 2017-03-14 | -$9.47 10-Q · filed 2016-08-15 | -$13.40 derived: net income ÷ weighted average shares · filed 2017-03-14 | -$3.06 derived: net income ÷ weighted average shares · filed 2017-03-14 | |
| 2015-03-31 | -$4.98 10-K · filed 2017-03-14 | -$8.91 derived: net income ÷ weighted average shares · filed 2017-03-14 | $1.44 derived: net income ÷ weighted average shares · filed 2017-03-14 | ||
| 2014-12-31 | -$3.88 10-K · filed 2016-03-23 | $6.47 derived: net income ÷ weighted average shares · filed 2017-03-14 | -$5.48 10-K · filed 2017-03-14 | ||
| 2014-09-30 | $10.35 10-K · filed 2016-03-23 | -$9.03 10-Q · filed 2015-11-13 | -$21.09 10-Q · filed 2015-11-13 | ||
| 2014-06-30 | -$6.39 10-K · filed 2016-03-23 | ||||
| 2014-03-31 | -$5.71 10-K · filed 2016-03-23 | ||||
| 2013-12-31 | -$20.72 10-K · filed 2016-03-23 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Immix Biopharma, Inc. (IMMX) | United States | $0.837B | -18.44 |
| Obsidian Therapeutics, Inc. (OBX) | United States | $0.829B | |
| ARDELYX, INC. (ARDX) | United States | $0.857B | -22.86 |
| LEXICON PHARMACEUTICALS, INC. (LXRX) | United States | $0.823B | -17.48 |
| GYRE THERAPEUTICS, INC. (GYRE) | United States | $0.818B | -24.71 |
| GERON CORP (GERN) | United States | $0.803B | -12.14 |
| Cryoport, Inc. (CYRX) | United States | $0.881B | -21.29 |
| Theravance Biopharma, Inc. (TBPH) | $0.885B | 16.40 | |
| Aclaris Therapeutics, Inc. (ACRS) | United States | $0.792B | -9.78 |
| RIGEL PHARMACEUTICALS INC (RIGL) | United States | $0.893B | 2.25 |